Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Knowledge & Innovation Lawyer

James P. Devendorf

Goodwin Procter

main

Devendorf James

Goodwin Associate James Devendorf, from Boston, practices in life sciences. Learn more about James's experience, recent cases and contact details today.

James P. Devendorf

Areas of Practice

Professional Activities

Professional Experience

Credentials

Education

JD2009

MA2006

BA2003

Admissions

Bars

Courts

Related Content

PepGen Completes $108 Million Initial Public Offering

Cast & Crew Signs Definitive Agreement To Acquire Backstage Holdings

Life Sciences Team Advises Amylyx Pharmaceuticals in its Upsized Initial Public Offering

Cint Acquires Lucid

Pear Therapeutics Becomes a Public Company Through Business Combination with Thimble Point Acquisition Corp.

Aura Biosciences Completes $75.6 Million Initial Public Offering

Toast Completes $1 Billion IPO

G Squared Ascend I and Transfix Enter into $1.1 Billion Business Combination Agreement

ERISA & Executive Compensation